Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of “Hold” from Analysts

Henry Schein, Inc. (NASDAQ:HSIC) has been given a consensus rating of “Hold” by the twelve brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $76.4167.

Several research firms have recently weighed in on HSIC. Evercore boosted their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Barrington Research set a $79.00 price target on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Morgan Stanley lifted their target price on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. boosted their target price on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th.

Henry Schein Trading Down 0.3%

Shares of Henry Schein stock opened at $78.19 on Friday. The stock has a market cap of $9.20 billion, a P/E ratio of 24.74, a P/E/G ratio of 2.33 and a beta of 0.88. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. Henry Schein has a 12-month low of $60.56 and a 12-month high of $82.80. The business’s 50 day moving average is $77.09 and its 200-day moving average is $71.29.

Institutional Trading of Henry Schein

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC lifted its position in Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after acquiring an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after purchasing an additional 229 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Henry Schein in the 1st quarter valued at $676,000. Vanguard Personalized Indexing Management LLC grew its holdings in Henry Schein by 3.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock valued at $341,000 after buying an additional 157 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in Henry Schein by 63.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 9,505 shares of the company’s stock worth $694,000 after buying an additional 3,675 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.